CAS: 23918-98-1; (2R,3R)-4-(6-Amino-9H-Purin-9-yl)-2,3-Dihydroxybutanoic Acid

该化合物是纯衍生物,自然产生的核素类比,主要以其在亚代氨基新陈代谢中的作用而著称,并存在于某些菌类中,特别是在蘑菇物种*Pleurotus ostretatus* (食用蘑菇)中; 氨酸盐,其特点是能够抑制酶S-denosylsylhomocysteine 氢lase,该物质在调节体内的登氧水平方面起着关键作用; 这种抑制可导致S-adonosylhocysteine的含量下降,并随后影响各种生物化学途径,包括涉及甲基化过程的菌类; 氨酸盐,已引起人们对其潜在健康惠益的兴趣,包括其对胆固醇新陈代谢和心血管健康的影响. 此外,它还显示出抗氧化性特性,有助于其潜在的治疗用途. 由于化学化合物, 氨酸盐在水和生理条件下稳定,使其成为研究的课题.

结构式图片

上下游产品

CAS号29789-09-1 5-(6-amino-puri... | CAS号35910-49-7 methyl 5-(6-ami... | CAS号25581-41-3 2,3-O-异亚丙基-D-赤酮酸内酯 | CAS号66224-66-6 6H-Purin-6-imin... | CAS号28875-69-6 2,3-O-cyclohexy...

合成工艺路线路线简述

    📜D-Eritadenine Ethyl Ester置于sodium Hydroxide体系中,用95.5%的收率获得4-(9-腺嘌呤)-D-鞘氨醇-2,3-二羟基丁酸
    参考文献:Synthesis And Antiviral Activity Of Stereoisomeric Eritadenines
    标题:Synthesis And Antiviral Activity Of Stereoisomeric Eritadenines
    摘要:D-厄利他呋喃核苷(ia)和l-厄利他呋喃核苷(iia)是从5-(腺嘌呤-9-基)-5-脱氧醛糖或对映异构的2,3-二取代的赤霉糖内酯(viiib,C,Xiv)制备而成.使用高碘酸盐在钌的存在下氧化甲基2,3-O-异丙基-D-核糖呋喃苷(ix),随后进行酸水解和硼氢化钠还原,得到l-核糖内酮(xi).将其2,3-O-异丙基衍生物经过碱水解,随后经过高碘酸盐氧化,硼氢化钠还原和与环己酮反应,得到2,3-O-环己基-L-赤霉糖内酯(xiv).[u-14C]-腺嘌呤与viiib缩合,经过酸水解,得到[u-14C-腺嘌呤]-D-厄利他呋喃核苷.通过高碘酸盐在钌的存在下氧化1-(腺嘌呤-9-基)-1-脱氧-2,3-O-异丙基脱氢醇(xvi)和(xvii),得到threo-厄利他呋喃核苷iii和iv.9-(2,2-二乙氧基乙基)腺嘌呤(xix)与丙二酸反应,得到4-(腺嘌呤-9-基)-3-丁烯酸(xxi);经过甲醇处理制备其甲酯(xxii),再与三乙胺异构化,得到甲基4-(腺嘌呤-9-基)-2-丁烯酸酯(xxiii).Xxiii的羟化反应得到d-和l-厄利他呋喃核苷的外消旋混合物(iii+iv).厄利他呋喃核苷ia和iia对牛痘病毒,麻疹病毒和水疱性口炎病毒具有活性.厄利他呋喃核苷ia也对副流感病毒和副流感病毒有效.总体而言,厄利他呋喃核苷的抗病毒活性按照d-赤霉糖(ia) > L-赤霉糖(iia) > D-和l-Threo(iii,Iv)的顺序递减.
    Doi:10.1135/cccc19821392

    海关参考信息

    专利信息


    专利号:US-10925977-B2
    优先权日:2006-10-05
    标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
    发明人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
    权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
    摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

    专利号:US-2005080260-A1
    优先权日:2003-04-22
    标 题 :Preparation of prodrugs for selective drug delivery
    发明人:MILLS RANDELL L; WU GUO-ZHANG
    摘要:Synthesis of a chemical compound having the formula A-B-C that may serve for applications such as drug delivery where A is a chemiluminescent, moiety, B is a photochromic moiety, and C is a biologically active moiety where A-B-C may serve as a prodrug. Novel synthetic methods of the present invention to form the prodrug comprised the steps of (1) forming a benzophenone, (2) forming a diaryl ethylene, (3) attaching a phthalimide moiety to at least one of the aryl groups of the ethylene to form a phthalimide-ethylene conjugate, (4) condensing two ethylene-phthalimide conjugates to form a phthalimide-pentadiene conjugate, (5) converting the phthalimide to the phthalhydrazide by reaction with hydrazine to form a carrier compound according to the present invention, and (6) reacting the carrier compound with an nucleophilic moiety of the drug to form the corresponding prodrug. Alternatively the carrier can be prepared by using the halo-substituted diaryl ethylene to make the corresponding cationic leuco dye-like compound with known methods. The cationic compound then is protected by reacting with a nucleophile and coupled with the aminophathalimide by palladium-catalyzed amination to form the protected phthalimide-pentadiene conjugate. The latter is refluxed with hydrazine to convert its phthalimide to the phthalhydrazide and acidified to give the carrier. An additional aspect of the present invention relates to the use of these compounds as antiviral agents for the treatment of viral infections such as HIV and as anticancer agents for the treatment of cancers such as bowel, lung, and breast cancer.

    专利号:KR-101513003-B1
    优先权日:2006-10-05
    标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy compositions and applications

    专利号:US-10814013-B2
    优先权日:2006-10-05
    标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications

    专利号:AU-2007308022-A2
    优先权日:2006-10-05
    标题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications

    专利号:AU-2007308022-A1
    优先权日:2006-10-05
    标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Afrin S, Rakib MA, Kim BH, Kim JO, Ha YL. Eritadenine from Edible Mushrooms Inhibits Activity of Angiotensin Converting Enzyme in Vitro. J Agric Food Chem. 2016 Mar 23;64(11):2263-8. doi: 10.1021/acs.jafc.5b05869. Epub 2016 Mar 14. doi: 10.1016/j.exppara.2010.04.007. Epub 2010 Apr 20.
    6: Shimada Y, Morita T, Sugiyama K. Dietary eritadenine and ethanolamine depress fatty acid desaturase activities by increasing liver microsomal phosphatidylethanolamine in rats. J Nutr. 2003 Mar;133(3):758-65. Epub 2013 Oct 8.
    9: Enman J, Rova U, Berglund KA. Quantification of the bioactive compound eritadenine in selected strains of shiitake mushroom (Lentinus edodes). J Agric Food Chem. 2007 Feb 21;55(4):1177-80. Epub 2007 Jan 27. Epub 2006 Aug 1. doi: 10.1021/jf800091a. Epub 2008 Mar 26. Epub 2006 Dec 14. Epub 2001 Dec 10. Review.

    合成参考文献


    摘要:Seela, F.; Ramzaeva, N.; Rosemeyer, H., Science of Synthesis, (2004) 16, 945.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知